Breaking News

AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery

HAYWARD, Calif., Jan. 12, 2022 /PRNewswire/ — AcelRx Prescribed drugs, Inc. (NASDAQ: ACRX), a specialty pharmaceutical firm concentrated on the development and commercialization of modern therapies for use in medically supervised options, right now declared the publication of an editorial concerning the use of sufentanil sublingual tablet (SST DSUVIA®) in total joint replacement surgical procedures […]